

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TYK Medicines, Inc

浙江同源康醫藥股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2410)

**ANNOUNCEMENT IN RELATION TO
DEALINGS IN SECURITIES OF A DIRECTOR
DURING THE BLACK-OUT PERIOD**

This announcement is made by TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the **“Company”**) pursuant to paragraph D.15 of Appendix C3 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the **“Listing Rules”**).

The board (the **“Board”**) of directors (**“Directors”**) of the Company has been notified by Dr. GU Eric Hong (**“Dr. Gu”**), a non-executive Director, that on August 20, 2025, Pivot Pharma Tech (Shanghai) Co., Ltd. (貝沃特醫藥技術(上海)有限公司), a company wholly-owned by Dr. Gu entered into an on-market transaction disposing of a total of 10,000 H shares (**“H Share(s)”**) of the Company at a consideration of HK\$14.99 per H Share (the **“Transfer”**) without first having notified the Company prior to the Transfer in accordance with the requirements paragraph B.8 of Appendix C3 to the Listing Rules. As a result of the Transfer, the beneficial shareholding interest in H Shares of Dr. Gu in the Company has been reduced from approximately 2.20% to 2.19% of the total issued H Shares capital of the Company as at the date of this announcement.

Pursuant to paragraph A.3 of Appendix C3 to the Listing Rules, the Directors are prohibited from dealing in any securities of the Company on any day on which its financial results are published and during the period of 30 days immediately preceding the publication date of the interim results of the Company for the six months ended June 30, 2025 (the **“Interim Results”**), as well as any period of delay in the publication of the Interim Results announcement (the **“Black-out Period”**). As disclosed in the announcement of the Company dated August 20, 2025, the meeting of the board of Directors for the publication of the Interim Results is scheduled on August 31, 2025 and the Transfer therefore fell within the Black-out Period and constituted a dealing of Shares by Dr. Gu and a non-compliance incident of paragraphs A.3 and B.8 of Appendix C3 to the Listing Rules (the **“Non-compliance Incident”**).

Dr. Gu reported the Non-compliance Incident to the Company and confirmed that the non-compliance was an inadvertent oversight and he did not intend to commit such breach. Dr. Gu further confirmed that he does not possess any inside information of the Company when the Transfer took place, and he will apply closer scrutiny towards Appendix C3 of the Listing Rules.

Upon becoming aware of the Non-compliance Incident, the Company has immediately reminded the Directors and senior management again of the requirements of the Appendix C3 to the Listing Rules and the importance of compliance with such provision. In order to ensure compliance with the Appendix C3 to the Listing Rules and prevent similar incidents in the future, the Company will provide regular training to the Directors, senior management and staff of the Company so as to keep them abreast of the relevant requirements. The Company will also circulate Appendix C3 to the Listing Rules and remind the Directors to compliance with its requirements in greater frequency to ensure compliance with and enhance their awareness of good corporate governance practices.

By order of the Board
TYK Medicines, Inc
(浙江同源康醫藥股份有限公司)

Dr. WU Yusheng
Chairman, Executive Director and Chief Executive Officer

Hong Kong, August 21, 2025

As at the date of this announcement, the Board comprises Dr. WU Yusheng as executive Director, Dr. LI Jun, Dr. GU Eric Hong, Dr. JIANG Mingyu, Dr. MENG Xiaoying, Mr. HE Chao and Dr. ZHU Xiangyang as non-executive Directors, and Mr. ZHANG Senquan, Dr. LENG Yuting, Dr. XU Wenqing and Dr. SHEN Xiuhua as independent non-executive Directors.